Deutsche Bank provided color on Covidien COV after Bloomberg published an article about the company's plans for its pharmaceuticals business.
In a research report published today, Deutsche Bank states, "Last evening a Bloomberg article stated that Covidien had been working
with an investment bank regarding options for the pharmaceuticals business... It stated
COV had been in talks with another healthcare company, but discussions
recently broke down though other potential buyers are still looking at the
business."
At the moment, Deutsche Bank has a Buy rating and a price target of $61 placed on the company's stock. On Tuesday, Covidien closed the day at $54.31.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in